AB Science SA (HAM:A8D) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares with share warrants attached (ABSA) Closed: €14.2M raised · €0.61 a share · 1 warrant at €1 for 60 months Buyers: Existing long-term investor (EUR 12 million); Stéphane Ledermann Insiders: The CEO, Stéphane Ledermann, also contributed to the financing Use of proceeds: Fund R&D programs, mainly AB8939 in acute myeloid leukemia, masitinib in ALS, and nearer-term value-creation projects | Aug 10, 2026 | US$16.4M |
| Private placement of new ordinary shares with share warrants attached (ABSA) Announced: €3.2M · €0.94 a share · Warrants at €1.3 for 48 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Finance ongoing activities, with a focus on the clinical development of the AB8939 program | Apr 29, 2026 | US$3.74M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €2.8M raised · €1.13 a share · Warrants at €1.72 for 60 months Use of proceeds: Finance ongoing activities, focusing on clinical development of AB8939: finish phase 1 and launch an AML expansion study | Oct 17, 2025 | US$3.27M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €2.55M raised · €1.12 a share · Warrants at €1.71 for 60 months Use of proceeds: To finance ongoing activities, with a focus on the clinical development of the AB8939 program | Aug 4, 2025 | US$2.94M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €1.93M raised · €1.17 a share · Warrants at €1.78 for 60 months Use of proceeds: Finance ongoing activities, with a focus on clinical development of the AB8939 program | Jul 8, 2025 | US$2.25M |
| Private placement of new shares Closed: €1.8M in the latest tranche · €1.17 a share · Warrants at €1.79 for 60 months · Maxim Group, LLC Dealers: Maxim Group, LLC (lead) Use of proceeds: Strengthens the cash position and covers financing needs in 2025 and beyond the next 12 months | May 23, 2025 |